Business
Edgewise Therapeutics to Showcase Novel Cardiac Program at Virtual Investor Event on Tuesday, January 3, 2023
– Webcast event to feature preclinical data of its lead hypertrophic cardiomyopathy (HCM) candidate and commentary by a renowned cardiologist – – Management
About this update from Edgewise Therapeutics, Inc.
[{"type":"text","content":"\n– Webcast event to feature preclinical data of its lead hypertrophic cardiomyopathy (HCM) candidate and commentary by a renowned cardiologist –\n\n– Management to provide 2023 Company outlook at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023 –\n\n BOULDER, Colo.--(BUSINESS WIRE)--\nEdgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle disorders, announced today plans to host a virtual investor call on Tuesday, January 3, 2023, at 8:30 am ET. The webcast event will feature a presentation of preclinical results for its lead cardiac program candidate, EDG-7500, initially targeting patients with HCM and will include commentary by a leading cardiology expert.\n\n“EDG-7500 represents Edgewise’s new investigational candidate coming out of our highly productive discovery platform targeting the identification of cardiovascular therapeutics with differentiated mechanisms of action,” said Kevin Koch, Ph.D., President and Chief Executive Officer, Edgewise Therapeutics. “We believe our preclinical data set around EDG-7500 suggests it can address important unmet medical needs in the treatment of HCM. We are planning to file an IND application in the second half of 2023.”\n\nA live webcast of the event will be available in the Events & Presentations page of Edgewise’s website and a replay will be accessible for a limited period of time following the event. An accompanying slide presentation will also be available. To register for the live webcast and replay, please visit the Edgewise events page.\n\nFurther, Edgewise plans to share these data and the Company’s 2023 outlook at the 41st Annual J.P. Morgan Healthcare conference on January 10, 2023.\n\nEdgewise Therapeutics Presentation at J.P. Morgan Annual Healthcare Conference\n\nEdgewise Therapeutics’ President and Chief Executive Officer, Kevin Koch, Ph.D., will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 12:45 pm ET / 9:45 am PT. The presentation will be webcast live; a link for the webcast can be found on the Edgewise events page and will be accessible for replay following the presentation. It is recommended that users connect to the webcast several minutes prior to the start ...